Compare FIRY & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIRY | ANIX |
|---|---|---|
| Founded | N/A | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.2M | 114.0M |
| IPO Year | 2020 | 2013 |
| Metric | FIRY | ANIX |
|---|---|---|
| Price | $10.31 | $2.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 104.9K | ★ 332.0K |
| Earning Date | N/A | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,496,000.00 | $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.52 | N/A |
| 52 Week Low | $7.92 | $2.32 |
| 52 Week High | $14.12 | $5.46 |
| Indicator | FIRY | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 57.16 | 34.84 |
| Support Level | $9.39 | $2.73 |
| Resistance Level | $10.87 | $3.09 |
| Average True Range (ATR) | 0.40 | 0.19 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 92.63 | 16.36 |
Firy Inc, formerly Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. Its reportable segments are: the Skillz segment and the RZR segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is a performance marketing platform that enables advertisers to acquire, retain, and monetize users across mobile, connected television (CTV), and other digital channels. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube, among others. It generates the majority of its revenue from the Skillz segment. Geographically, the company derives its key revenue from the United States.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.